title: [A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].
abstract: We report a patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel (TXL) as the third line treatment and could take meals for half a year. The patient was a 64-year-old man who underwent total gastrectomy for advanced gastric cancer with peritoneal metastasis. He was first treated with TS-1 as an outpatient treatment; however, tumor markers rose. He could not take meals and had to be hospitalized. CPT-11 was infused on the second line, but due to disease progress, the patient was administered weekly TXL. TXL (70 mg/m2) was infused over 1 hour after short premedication. Administration was continued for 3 weeks followed by 1 week rest. The tumor markers decreased, and he could take meals and was discharged from hospital. The toxic events were leukopenia (grade 2), alopecia (grade 2) and pneumonia (grade 3).
authors.affiliation: Dept. of Surgery, Saiseikai Nakatsu Hospital.
authors.forename: Shiro
authors.initials: S
authors.lastname: Nakae
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Urakawa
authors.forename: Masashi
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Hisoka
authors.initials: H
authors.lastname: Kinoshita
authors.forename: Kazue
authors.initials: K
authors.lastname: Sainoh
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kitaura
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Shintaro
authors.initials: S
authors.lastname: Takao
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiroiwa
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Onoyama
authors.forename: Syunichi
authors.initials: S
authors.lastname: Sugihara
authors.forename: Jo
authors.initials: J
authors.lastname: Toyota
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Saitoh
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D017640:Silicates / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology*; D014025:Titanium / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D017640:Silicates; C103828:titanium silicide; D000077146:Irinotecan; D014025:Titanium; D017239:Paclitaxel; D002166:Camptothecin